<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1059</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2025-20-3-120-132</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SUPPORTIVE THERAPY ASPECTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Adherence to treatment in patients with multiple myeloma and pain syndrome</article-title><trans-title-group xml:lang="ru"><trans-title>Приверженность лечению у пациентов с множественной миеломой и болевым синдромом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7506-4947</contrib-id><name-alternatives><name xml:lang="en"><surname>Vybornykh</surname><given-names>D. E.</given-names></name><name xml:lang="ru"><surname>Выборных</surname><given-names>Д. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dmitry Eduardovich Vybornykh</p><p>4 Novyy Zykovskiy Proezd, Moscow 125167</p></bio><bio xml:lang="ru"><p>Дмитрий Эдуардович Выборных</p><p>125167 Москва, Новый Зыковский пр-д, 4</p></bio><email>dvyb@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2013-9507</contrib-id><name-alternatives><name xml:lang="en"><surname>Irugova</surname><given-names>Z. E.</given-names></name><name xml:lang="ru"><surname>Иругова</surname><given-names>Э. З.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Novyy Zykovskiy Proezd, Moscow 125167</p></bio><bio xml:lang="ru"><p>125167 Москва, Новый Зыковский пр-д, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7253-5694</contrib-id><name-alternatives><name xml:lang="en"><surname>Esina</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Есина</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Novyy Zykovskiy Proezd, Moscow 125167</p><p>Build. 2, 8 Trubetskaya St., Moscow 119991</p></bio><bio xml:lang="ru"><p>125167 Москва, Новый Зыковский пр-д, 4</p><p>119991 Москва, ул. Трубецкая, 8, стр. 2</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8239-5442</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>S. Yu.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>С. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Novyy Zykovskiy Proezd, Moscow 125167</p></bio><bio xml:lang="ru"><p>125167 Москва, Новый Зыковский пр-д, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7944-6202</contrib-id><name-alternatives><name xml:lang="en"><surname>Solov’ev</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Соловьев</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Novyy Zykovskiy Proezd, Moscow 125167</p></bio><bio xml:lang="ru"><p>125167 Москва, Новый Зыковский пр-д, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4142-171X</contrib-id><name-alternatives><name xml:lang="en"><surname>Solov’eva</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Соловьева</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Novyy Zykovskiy Proezd, Moscow 125167</p></bio><bio xml:lang="ru"><p>125167 Москва, Новый Зыковский пр-д, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4966-8146</contrib-id><name-alternatives><name xml:lang="en"><surname>Mendeleeva</surname><given-names>L. P.</given-names></name><name xml:lang="ru"><surname>Менделеева</surname><given-names>Л. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>4 Novyy Zykovskiy Proezd, Moscow 125167</p></bio><bio xml:lang="ru"><p>125167 Москва, Новый Зыковский пр-д, 4</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center for Hematology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-09-11" publication-format="electronic"><day>11</day><month>09</month><year>2025</year></pub-date><volume>20</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>120</fpage><lpage>132</lpage><history><date date-type="received" iso-8601-date="2025-09-11"><day>11</day><month>09</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-09-11"><day>11</day><month>09</month><year>2025</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/1059">https://oncohematology.abvpress.ru/ongm/article/view/1059</self-uri><abstract xml:lang="en"><p><bold>Background</bold>. Treatment adherence is one of the key factors influencing the therapy outcome in patients with multiple myeloma complicated by pain syndrome.<bold>Aim</bold>. To clarify the treatment adherence features in patients with multiple myeloma.<bold>Materials and methods</bold>. The data of 61 patients with pain syndrome associated with bortezomib-induced polyneuropathy and oral mucositis were studied. Men – 17 (27.9 %), women – 44 (72.1 %). Median age – 52 (31–67) years. Assessment of pain syndrome and psychometric parameters of patients was performed in hospital before autologous hematopoietic stem cell transplantation (1st point), on the 8th (2nd point) and 100th (3rd point) days after transplantation. Validated algometric and psychometric methods were used.<bold>Results</bold>. At each study point, patients with high adherence were grouped into 1st group, and patients with low adherence were grouped into 2nd group. At 1st point, statistically significant differences were noted between the groups in such indicators as quality of life / satisfaction and the degree of polyneuropathy. At the 2nd point, significant differences were found in the types of patient’s attitude toward illness: in the 1st group, adaptive types (harmonious, ergopathic) predominated, in the 2nd – maladaptive ones (anxious, neurasthenic, and sensitive). At 3rd point, a statistically significant difference was noted between the groups in the severity of mental disorders symptoms, the presence of which may be associated with decreased adherence to treatment, as well as the presence exclusively in the group with a low treatment adherence a maladaptive (egocentric) type of attitude toward illness.<bold>Conclusion</bold>. Adherence to treatment in patients with multiple myeloma complicated by pain syndrome is a complex problem that requires a multidisciplinary team of specialists, which should include hematologists, algologists, and mental health specialists (psychiatrists, medical psychologists).</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. Приверженность лечению является одним из ключевых факторов, влияющих на результат терапии пациентов с множественной миеломой, осложненной болевым синдромом.<bold>Цель исследования</bold> – уточнить особенности приверженности лечению у больных множественной миеломой.<bold>Материалы и методы</bold>. Изучены данные 61 пациента с болевым синдромом, ассоциированным с бортезомибиндуцированной полинейропатией и мукозитом ротовой полости. Число мужчин – 17 (27,9 %), женщин – 44 (72,1 %). Медиана возраста – 52 (31–67) года. Оценку болевого синдрома и психометрических показателей больных проводили перед выполнением аутологичной трансплантации гемопоэтических стволовых клеток (1‑я точка), на 8‑й (2‑я точка) и 100‑й (3‑я точка) дни после трансплантации. Использовали валидизированные алгометрические и психометрические методы.<bold>Результаты</bold>. На каждой точке исследования пациенты с высокой приверженностью объединялись в 1‑ю группу, с низкой приверженностью – во 2‑ю. На 1‑й точке отмечались статистически значимые различия между группами по таким показателям, как качество жизни / удовлетворенность и степень полинейропатии. На 2‑й точке обнаруживались значимые различия по типам отношения к болезни: в 1‑й группе отмечалось преобладание адаптивных типов отношения к болезни (гармоничный, эргопатический), во 2‑й – дезадаптивных (тревожный, неврастенический, сенситивный). На 3‑й точке отмечались статистически значимое различие между группами по выраженности симптомов психических расстройств, наличие которых может ассоциироваться со снижением приверженности лечению, а также наличие исключительно в группе с низким уровнем приверженности терапии дезадаптивного (эгоцентрического) типа отношения к болезни.<bold>Заключение</bold>. Приверженность лечению у больных множественной миеломой, осложненной болевым синдромом, представляет собой комплексную проблему, решать которую призвана мультидисциплинарная команда специалистов, в состав которой должны входить как врачи-гематологи, врачи-алгологи, так и специалисты в области психического здоровья (психиатры, медицинские психологи).</p></trans-abstract><kwd-group xml:lang="en"><kwd>multiple myeloma</kwd><kwd>pain syndrome</kwd><kwd>treatment adherence</kwd><kwd>type of attitude toward illness</kwd><kwd>mental disorder</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>множественная миелома</kwd><kwd>болевой синдром</kwd><kwd>приверженность лечению</kwd><kwd>тип отношения к болезни</kwd><kwd>психическое расстройство</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Zhuge L., Lin X., Fan Z. et al. Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. Front Public Health 2025;13(27):1527198. DOI: 10.3389/fpubh.2025.1527198</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Rajkumar S.V. Multiple myeloma: 2024 update on diagnosis, riskstratification, and management. Am J Hematol 2024;99(9):1802–24. DOI: 10.1002/ajh.27422</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Gackowski M., Jasińska-Stroschein M., Osmałek T., Waszyk-Nowaczyk M. Innovative approaches to enhance and measure medication adherence in chronic disease management: a review. Med Sci Monit 2024;30:e944605. DOI: 10.12659/MSM.944605</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Guio J., Melo A., Saldarriaga M.M. et al. A novel digital educational strategy improves treatment adherence and quality of life in patients with multiple myeloma. J Cancer Educ 2024;39(1):50–7. DOI: 10.1007/s13187-023-02374-w</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Amonoo H.L., Deary E.C., Wang A. et al. Medication adherence in patients with hematologic malignancies who are hematopoietic stem cell transplantation survivors: a qualitative study. Transplant Cell Ther 2023;29(10):620.e1–11. DOI: 10.1016/j.jtct.2023.07.019</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Derakhshan A., Mansouri A., Jafarzadeh Kohneloo A., Hadjibabaie M. Adherence to immunosuppressants among adult patients after allogeneic hematopoietic stem-cell transplantation (allo-HSCT): a cross-sectional study. Int J Hematol Oncol Stem Cell Res 2022;17(4):231–9. DOI: 10.18502/ijhoscr.v17i4.13913</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Visintini C., Mansutti I., Palese A. Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review. Cancers (Basel) 2023;15(9):2452. DOI: 10.3390/cancers15092452</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Visintini C., Lucchetta C., Venturini M. et al. Perspective on oral medication adherence among patients with acute graft-versus-host disease: a qualitative descriptive study. Support Care Cancer 2024;32(10):633. DOI: 10.1007/s00520-024-08825-4</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ice L.L., Bartoo G.T., McCullough K.B. et al. A prospective survey of outpatient medication adherence in adult allogeneic hematopoietic stem cell transplantation patients. Biol Blood Marrow Transplant 2020;26(9):1627–34. DOI: 10.1016/j.bbmt.2020.05.020</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Belaiche S., Décaudin B., Caron A. et al. Medication nonadherence after allogeneic hematopoietic cell transplantation in adult and pediatric recipients: a cross-sectional study. Fundam Clin Pharmacol 2021;35(2):435–45. DOI: 10.1111/fcp.12593</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Kolgaeva E.I., Drokov M.Yu., Vybornykh D.E. Treatment adherence in patients with blood system diseases and recipients of allogeneic organs and tissues. Onkogematologiya = Oncohematology 2023;18(1):132–41. (In Russ.). DOI: 10.17650/1818‑8346‑2023‑18‑1‑132‑141</mixed-citation><mixed-citation xml:lang="ru">Кольгаева Э.И., Дроков М.Ю., Выборных Д.Э. Приверженность к лечению у пациентов с заболеваниями системы крови и реципиентов аллогенных органов и тканей. Онкогематология 2023;18(1):132–41. DOI: 10.17650/1818‑8346‑2023‑18‑1‑132‑141</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Irugova E.Z., Mendeleeva L.P., Vybornykh D.E. et al. Bortezomibinduced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects. Onkogematologiya = Oncohematology 2025;20(1):154–64. (In Russ.). DOI: 10.17650/1818‑8346‑2025‑20‑1‑154-164</mixed-citation><mixed-citation xml:lang="ru">Иругова Э.З., Менделеева Л.П., Выборных Д.Э. и др. Бортезомибиндуцированная периферическая полинейропатия у больных множественной миеломой. Онкогематология 2025;20(1):154–64. DOI: 10.17650/1818-8346-2025-20-1-154-164</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Chang X., Yao S., Wei J. et al. The validation and cross-cultural adaptation of the PainDETECT questionnaire in osteoarthritisrelated pain. J Orthop Surg Res 2025;20(1):94. DOI: 10.1186/s13018-025-05510-y</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Lanfredini R., Cipriani L. The experience of pain and its ontological modelling from a philosophical point of view: phenomenological description and ontological revision of the McGill Pain Questionnaire. J Eval Clin Pract 2023;29(7):1211–21. DOI: 10.1111/jep.13879</mixed-citation></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Radchikova N.P., Adashinskaya G.A., Sanoyan T.R., Shupta A.A. Russian adaptation of the pain catastrophizing scale. Klinicheskaya i specialnaya psihologiya = Clinical Psychology and Special Education 2020;4(9):169–87. (In Russ.). DOI: 10.17759/cpse.2020090409</mixed-citation><mixed-citation xml:lang="ru">Радчикова Н.П., Адашинская Г.А., Саноян Т.Р., Шупта А.А. Шкала катастрофизации боли: адаптация опросника. Клиническая и специальная психология 2020;4(9):169–87. DOI: 10.17759/cpse.2020090409</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Hofmann A.B., Schmid H.M., Jabat M. et al. Utility and validity of the Brief Psychiatric Rating Scale (BPRS) as a transdiagnostic scale. Psychiatry Res 2022;314:114659. DOI: 10.1016/j.psychres.2022.114659</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Snodgrass M.A., Bieu R.K., Schroeder R.W. Development of a symptom validity index for the Beck Anxiety Inventory. Clin Neuropsychol 2024;15:1–16. DOI: 10.1080/13854046.2024.2429162</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Shura R.D., Schroeder R.W., Ord A.S. et al. Symptom validity indices for the Beck Depression Inventory – II: development and cross-validation. Clin Neuropsychol 2024;22:1–19. DOI: 10.1080/13854046.2024.2432058</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Wasserman L.I., Iovlev B.V., Karpova E.B., Vuks A.Y. Psychological diagnosis of attitudes toward illness: physician manual. Saint Petersburg: NIPNI im. Bekhtereva, 2005. 33 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Вассерман Л.И., Иовлев Б.В., Карпова Э.Б., Вукс А.Я. Психологическая диагностика отношения к болезни: пособие для врачей. СПб.: НИПНИ им. Бехтерева, 2005. 33 с.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Nikolaev N.A., Skirdenko Yu.P. Russian universal questionnaire for quantitative assessment of treatment adherence (QAP-25). Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapeutics 2018;1(27):74–8. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Николаев Н.А., Скирденко Ю.П. Российский универсальный опросник количественной оценки приверженности к лечению (КОП-25). Клиническая фармакология и терапия 2018;1(27):74–8.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Rasskazova E.I. Evaluation of quality of life enjoyment and satisfaction: psychometric properties of a Russian-language measure. Psikhologiya. Zhurnal Vysshey shkoly ekonomiki = Psychology. Journal of Higher School of Economics 2012;4(9): 81–90. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Рассказова Е.И. Методика оценки качества жизни и удовлетворенности: психометрические характеристики русскоязычной версии. Психология. Журнал Высшей школы экономики 2012;4(9):81–90.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Irugova E.Z., Vybornykh D.E., Gemdzhian E.G. et al. Pain syndrome and mental disorders in patients with multiple myeloma and post-transplantation oral mucositis. Kremlevskaya meditsina. Klinicheskij vestnik = Kremlin Medicine Journal 2024;4:62–8. (In Russ.). DOI: 10.48612/cgma/5fbb-64pn-xxed</mixed-citation><mixed-citation xml:lang="ru">Иругова Э.З., Выборных Д.Э., Гемджян Э.Г. и др. Болевой синдром и психические нарушения при посттрансплантационном мукозите. Кремлевская медицина. Клинический вестник 2024;4:62–8. DOI: 10.48612/cgma/5f bb-64pn-xxed</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><mixed-citation>Foulon V., Schöffski P., Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 2011;66(2):85–96. DOI: 10.2143/ACB.66.2.2062525</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Bouwman L., Eeltink C.M., Visser O. et al. Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation. BMC Cancer 2017;17(1):739. DOI: 10.1186/s12885-017-3735-1</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Hall A.E., Paul C., Bryant J. et al. To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol 2016;97:247–62. DOI: 10.1016/j.critrevonc.2015.08.025</mixed-citation></ref></ref-list></back></article>
